Snapshot from Aug 14, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Technology / DT-109 reverses MASH in animal models
Tech medical breakthrough

DT-109 reverses MASH in animal models

Analysis based on 10 articles · First reported Jul 07, 2026 · Last updated Jul 09, 2026

Sentiment
40
Attention
3
Articles
10
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The discovery of DT-109's mechanism and its potential to treat MASH, a condition affecting 7% of the global population, could drive significant interest in Diapin Therapeutics and related biotech stocks. However, as the drug is still in preclinical stages, near-term market impact is limited.

Pharmaceuticals Biotechnology
Event Summary

Researchers at University of Michigan Medicine discovered that the glycine-based tripeptide DT-109 reverses metabolic dysfunction-associated steatohepatitis (MASH) in animal models by protecting the gut barrier and reducing harmful gut bacteria. The study, published in Journal of Clinical Investigation, shows DT-109 diminishes Clostridium perfringens and ammonia production, reducing liver inflammation. The compound also shows potential for treating cardiovascular disease and inflammatory bowel disease. The University of Michigan has patented DT-109 and licensed it to Diapin Therapeutics, which provided the compound for the study. Future studies will advance DT-109 toward clinical trials.

Key Actions
80 University of Michigan Medicine discovered drug treats MASH
70 Eugene Chua led study on DT-109
50 Diapin Therapeutics provided DT-109 for study University of Michigan Medicine
Entities Involved
priv
University of Michigan Medicine
University of Michigan Medicine led the research and discovery of DT-109's efficacy against MASH, enhancing its reputation in medical research.
Importance 100.0 Sentiment 50.0
per
Eugene Chua
Senior author of the study and inventor of DT-109, his work is central to the discovery.
Importance 90.0 Sentiment 50.0
priv
Diapin Therapeutics
Licensee of DT-109, provided the compound for the study, and is further developing it, positioning itself for potential market entry.
Importance 70.0 Sentiment 60.0
per
Jifeng Zhang
Co-author and research professor who contributed to understanding DT-109's mechanism.
Importance 60.0 Sentiment 40.0
per
Elliot Tapper
Academic director of hepatology at University of Michigan Medicine, commented on the study's significance.
Importance 40.0 Sentiment 30.0
oth
Xi an Jiaotong University
Involved in ethical approval and nonhuman primate studies, supporting the research.
Importance 30.0 Sentiment 20.0
oth
Jinan University
Provided ethical approval for human protocol, minor role.
Importance 20.0 Sentiment 10.0
priv
Spring Biological Technology Development Company
Provided animal care approval for nonhuman primate studies, minor role.
Importance 20.0 Sentiment 10.0
govactor
United States — National Institutes of Health
Provided guidelines for animal care, not directly involved.
Importance 10.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.